NO20092374L - Forbindelser som har bade angiotensin II receptorantagonisme og PPARy aktiverende aktiviteter - Google Patents

Forbindelser som har bade angiotensin II receptorantagonisme og PPARy aktiverende aktiviteter

Info

Publication number
NO20092374L
NO20092374L NO20092374A NO20092374A NO20092374L NO 20092374 L NO20092374 L NO 20092374L NO 20092374 A NO20092374 A NO 20092374A NO 20092374 A NO20092374 A NO 20092374A NO 20092374 L NO20092374 L NO 20092374L
Authority
NO
Norway
Prior art keywords
compounds
angiotensin
receptor antagonism
activating activities
pparγ activating
Prior art date
Application number
NO20092374A
Other languages
English (en)
Inventor
Christopher Franklin Bigge
Agustin Casimiro-Garcia
Chitase Lee
Hud Lawrence Risley
Robert Philip Schaum
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20092374L publication Critical patent/NO20092374L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser av følgende formel (I) er tilveiebrakt som har både angiotensin II receptorantagonistaktivitet og PPARy agonistaktivitet. Også tilveiebrakt er farmasøytiske sammensetninger omfattende forbindelsene og fremgangsmåter for behandling av sykdommer med forbindelsene inkluderende type 2 diabetes, insulinresistens, hyperinsulinemi, hyperlipidemi, hypertriglyceridemi, metabolsk syndrom, kongestiv hjertesvikt og hypertensjon.
NO20092374A 2006-12-21 2009-06-22 Forbindelser som har bade angiotensin II receptorantagonisme og PPARy aktiverende aktiviteter NO20092374L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87633406P 2006-12-21 2006-12-21
US97065307P 2007-09-07 2007-09-07
PCT/IB2007/003844 WO2008084303A1 (en) 2006-12-21 2007-12-03 Compounds having both angiotensin ii receptor antagonism and ppary activating activities

Publications (1)

Publication Number Publication Date
NO20092374L true NO20092374L (no) 2009-09-15

Family

ID=39284139

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092374A NO20092374L (no) 2006-12-21 2009-06-22 Forbindelser som har bade angiotensin II receptorantagonisme og PPARy aktiverende aktiviteter

Country Status (9)

Country Link
US (1) US20100029710A1 (no)
EP (1) EP2125806A1 (no)
JP (1) JP2010513457A (no)
KR (1) KR20090091356A (no)
AU (1) AU2007343139A1 (no)
CA (1) CA2671943A1 (no)
MX (1) MX2009006795A (no)
NO (1) NO20092374L (no)
WO (1) WO2008084303A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2420501A4 (en) 2009-04-17 2012-08-29 Kowa Co NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4- (3H) -ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME
US20120046308A1 (en) 2009-05-29 2012-02-23 Kowa Company, Ltd. Novel alpha-phenoxybenzeneacetic acid derivative and pharmaceutical preparation comprising same
US20120122906A1 (en) 2009-08-27 2012-05-17 Kowa Company, Ltd. Novel sulfonamide derivative and pharmaceutical product containing same
JP5583681B2 (ja) 2009-09-29 2014-09-03 興和株式会社 新規なフェニルピリジン誘導体及びこれを含有する医薬
CA2784710A1 (en) * 2009-12-15 2011-06-23 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
MX2012013560A (es) * 2010-05-24 2013-03-05 Univ Vanderbilt 6-metilnicotinamidas sustituidas como moduladores alostéricos positivos de mglur5.
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
PL2687523T3 (pl) 2011-03-14 2016-06-30 Kowa Co Nowa pochodna fenylopirydyny i lek zawierający ją
WO2012158550A2 (en) * 2011-05-13 2012-11-22 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
US9135515B2 (en) 2012-10-22 2015-09-15 Qiagen Gaithersburg, Inc. Automated pelletized sample vision inspection apparatus and methods
US9212976B2 (en) * 2013-03-15 2015-12-15 Qiagen Gaithersburg, Inc. Vision-guided aspiration apparatus and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure

Also Published As

Publication number Publication date
US20100029710A1 (en) 2010-02-04
KR20090091356A (ko) 2009-08-27
MX2009006795A (es) 2009-07-03
CA2671943A1 (en) 2008-07-17
WO2008084303A1 (en) 2008-07-17
AU2007343139A1 (en) 2008-07-17
JP2010513457A (ja) 2010-04-30
EP2125806A1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
WO2010036613A8 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
NO20084318L (no) Inhibitorer av II-beta-hydroksystereoid dehydrogenase I
CY1109842T1 (el) Αναστολεις της αφυδρογονασης 11-β-υδροξυστεροειδων i
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
DE602007007211D1 (de) Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1
WO2008112938A3 (en) Composition and method for the treatment of diseases affected by a peptide receptor
DK2114933T3 (da) Piperidin-GPCR-agonister
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
CL2010001496A1 (es) Compuestos derivados de (piridin-o pirimidin-)piperidina, agonistas de gpr119; composicion farmaceutica; y su uso para el tratamiento de la diabetes de tipo i, diabetes de tipo ii y enfermedades relacionadas tales como sindrome metabolico, dislipidemia y resistencia a la insulina.
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
DK2049513T3 (da) Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
MX2009007023A (es) Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos.
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
EA201100255A1 (ru) 5-алкинилпиримидины
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application